Indusatumab vedotin (MLN-0264, AKT-264) is an antibody-drug conjugate (ADC) that combines a human anti-guanylate cyclase C (GCC) antibody with the microtubule-disruptor monomethyl auristatin E, demonstrating anti-proliferative effects on pancreatic cancer cell lines by arresting the cell cycle at the G2/M phase and inducing apoptosis [1].